2664
CAWACHI LIMITED
カワチ薬品
- Industry
- Retail Trade
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Mar 2022
279,462
Mar 2023
281,871
Mar 2024
285,960
Mar 2025
287,816
Mar 2026
284,492
Operating profit(million JPY)
Mar 2022
7,709
Mar 2023
6,611
Mar 2024
7,601
Mar 2025
7,461
Mar 2026
6,779
Operating profit margin(%)
Mar 2022
2.76
Mar 2023
2.35
Mar 2024
2.66
Mar 2025
2.59
Mar 2026
2.38
Profit before tax(million JPY)
Mar 2022
7,687
Mar 2023
6,572
Mar 2024
7,153
Mar 2025
6,827
Mar 2026
5,572
Profit(million JPY)
Mar 2022
4,830
Mar 2023
4,177
Mar 2024
4,713
Mar 2025
4,884
Mar 2026
3,200
Total assets(million JPY)
Mar 2022
191,721
Mar 2023
194,496
Mar 2024
196,119
Mar 2025
199,601
Mar 2026
199,614
Cash and cash equivalents(million JPY)
Mar 2022
38,959
Mar 2023
38,450
Mar 2024
35,623
Mar 2025
36,674
Mar 2026
38,112
Cash flows from operating activities(million JPY)
Mar 2022
6,868
Mar 2023
9,817
Mar 2024
6,402
Mar 2025
7,481
Mar 2026
8,865
Cash flows from investing activities(million JPY)
Mar 2022
-4,536
Mar 2023
-5,840
Mar 2024
-5,291
Mar 2025
-4,515
Mar 2026
-5,156
Cash flows from financing activities(million JPY)
Mar 2022
-4,607
Mar 2023
-4,485
Mar 2024
-3,937
Mar 2025
-1,915
Mar 2026
-2,270
Return on equity(%)
Mar 2022
4.7
Mar 2023
3.9
Mar 2024
4.3
Mar 2025
4.3
Mar 2026
2.8
Equity ratio(%)
Mar 2022
54.5
Mar 2023
55.3
Mar 2024
56.7
Mar 2025
57.3
Mar 2026
58
Earnings per share(JPY per share)
Mar 2022
216.44
Mar 2023
187.06
Mar 2024
211.03
Mar 2025
218.72
Mar 2026
143.3
Net assets per share(JPY per share)
Mar 2022
4,682.61
Mar 2023
4,818.93
Mar 2024
4,980.82
Mar 2025
5,120.32
Mar 2026
5,188.27
Dividend per share(JPY per share)
Mar 2022
50
Mar 2023
50
Mar 2024
80
Mar 2025
80
Mar 2026
100
Payout ratio(%)
Mar 2022
23.1
Mar 2023
26.73
Mar 2024
37.91
Mar 2025
36.58
Mar 2026
69.78
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.